Literature DB >> 28914427

The clinical and genetic Spectrum of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia.

Nouriya Abbas Al-Sannaa1, Hind Yousif Al-Abdulwahed2, Sami Ibrahim Al-Majed2, Issam Hassan Bouholaigah2.   

Abstract

Mucopolysaccharidosis (MPS VI) or Maroteaux-Lamy syndrome is an autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine 4-sulfatase or arylsulfatase B. It is involved in the degradation of glycosaminoglycans and characterized by a wide spectrum of clinical and genetic heterogeneity. So far, more than 150 mutations have been reported in the ARSB gene. Most of these mutations are either novel, private, or compound heterozygous making phenotype-genotype correlation as well as population screening difficult. The aim of our study is to determine the genotypes and phenotypes of MPS VI among the Saudi population at the Eastern Province of Saudi Arabia. The clinical data of all the patients seen and diagnosed with MPS VI (Maroteaux-Lamy syndrome) at the main hospital from January 1, 1983, to December 31, 2016, were reviewed. A total of 18 patients from 6 unrelated consanguineous families (first-cousin parents) were diagnosed with MPS VI during the defined 33 years. All of the affected patients displayed the severe phenotype of MPS VI. Only one genotype (c.753C > Gp.Y251X) was identified among five of the studied families. All of those families were inhabitants of Al-Hofuf area, but they descended from different clans. A second genotype (c270_274del5bp pc.91Afs*34) was detected in a single family who had originated from Abha area (the southern-west region of the country). This report demonstrated the homogeneity for both phenotype and genotype of our studied patients with MPS VI. This may eventually make selective asymptomatic carrier test and newborn screening highly feasible in this region of country.

Entities:  

Year:  2017        PMID: 28914427      PMCID: PMC5752655          DOI: 10.1007/s12687-017-0329-1

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  16 in total

Review 1.  Management guidelines for mucopolysaccharidosis VI.

Authors:  Roberto Giugliani; Paul Harmatz; James E Wraith
Journal:  Pediatrics       Date:  2007-08       Impact factor: 7.124

2.  Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI.

Authors:  D Sillence; K Waters; S Donaldson; P J Shaw; C Ellaway
Journal:  JIMD Rep       Date:  2011-09-06

3.  Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

Authors:  Paul Harmatz; Roberto Giugliani; Ida Schwartz; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; J Edmond Wraith; Michael Beck; Laila Arash; Maurizio Scarpa; Zi-Fan Yu; Janet Wittes; Kenneth I Berger; Mary S Newman; Ann M Lowe; Emil Kakkis; Stuart J Swiedler
Journal:  J Pediatr       Date:  2006-04       Impact factor: 4.406

4.  Consanguinity among the Saudi Arabian population.

Authors:  M A el-Hazmi; A R al-Swailem; A S Warsy; A M al-Swailem; R Sulaimani; A A al-Meshari
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

5.  Database of the clinical phenotypes, genotypes and mutant arylsulfatase B structures in mucopolysaccharidosis type VI.

Authors:  Seiji Saito; Kazuki Ohno; Masakazu Sekijima; Toshihiro Suzuki; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2012-02-16       Impact factor: 3.172

6.  Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study.

Authors:  J J McGill; A C Inwood; D J Coman; M L Lipke; D de Lore; S J Swiedler; J J Hopwood
Journal:  Clin Genet       Date:  2009-11-23       Impact factor: 4.438

Review 7.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

8.  Mutational analysis of 105 mucopolysaccharidosis type VI patients.

Authors:  Litsa Karageorgos; Doug A Brooks; Anthony Pollard; Elizabeth L Melville; Leanne K Hein; Peter R Clements; David Ketteridge; Stuart J Swiedler; Michael Beck; Roberto Giugliani; Paul Harmatz; James E Wraith; Nathalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; John J Hopwood
Journal:  Hum Mutat       Date:  2007-09       Impact factor: 4.878

9.  Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence.

Authors:  Gunilla Malm; Allan M Lund; Jan-Eric Månsson; Arvid Heiberg
Journal:  Acta Paediatr       Date:  2008-08-04       Impact factor: 2.299

10.  Mucopolysaccharidosis type VI: a predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene.

Authors:  Agnieszka Jurecka; Ekaterina Zakharova; Loreta Cimbalistiene; Nina Gusina; Anna Kulpanovich; Adam Golda; Violetta Opoka-Winiarska; Ewa Piotrowska; Elena Voskoboeva; Anna Tylki-Szymańska
Journal:  Am J Med Genet A       Date:  2013-04-30       Impact factor: 2.802

View more
  5 in total

1.  Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.

Authors:  Min-Ju Chan; Hsuan-Chieh Liao; Michael H Gelb; Chih-Kuang Chuang; Mei-Ying Liu; Hsiao-Jan Chen; Shu-Min Kao; Hsiang-Yu Lin; You-Hsin Huang; Arun Babu Kumar; Naveen Kumar Chennamaneni; Nagendar Pendem; Shuan-Pei Lin; Chuan-Chi Chiang
Journal:  J Pediatr       Date:  2018-11-06       Impact factor: 4.406

Review 2.  Misdiagnosis in mucopolysaccharidoses.

Authors:  Karolina Wiśniewska; Jakub Wolski; Lidia Gaffke; Zuzanna Cyske; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  J Appl Genet       Date:  2022-05-13       Impact factor: 2.653

Review 3.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

4.  A steroid-resistant nephrotic syndrome in an infant resulting from a consanguineous marriage with COQ2 and ARSB gene mutations: a case report.

Authors:  Xia Wu; Wenhong Wang; Yan Liu; Wenyu Chen; Linsheng Zhao
Journal:  BMC Med Genet       Date:  2019-10-28       Impact factor: 2.103

Review 5.  Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.

Authors:  Francesca D'Avanzo; Alessandra Zanetti; Concetta De Filippis; Rosella Tomanin
Journal:  Int J Mol Sci       Date:  2021-12-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.